Amylyx Pharmaceuticals

Senior Director, Clinical Pharmacology

Cambridge, Massachusetts, United States

Amylyx Pharmaceuticals Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
PharmaceuticalsIndustries

Requirements

The Senior Director of Clinical Pharmacology should possess experience and expertise in matrixed leadership and team management, with a strong understanding of PK, PD, and immunogenicity properties of drugs and drug candidates. They require experience in clinical pharmacology strategy development from pre-IND through post-approval, including the design and implementation of clinical pharmacology studies, data analysis, and interaction with regulatory authorities. Additionally, they should have expertise in integrating clinical pharmacology knowledge with related disciplines like clinical, statistics, and regulatory affairs, and possess experience in population PK, PK/PD modeling and simulation, as well as preclinical PK/PD studies.

Responsibilities

As the Senior Director, the individual will serve as the clinical pharmacologist for the company, providing strategic and scientific input across all clinical programs, leading the Clinical Pharmacology team accountable for the clinical pharmacology strategy, integrating clinical pharmacology knowledge with related disciplines, ensuring appropriate PK, PD, and PK/PD data analyses, collaborating with toxicologists and preclinical pharmacology scientists, ensuring adherence to timelines and budgets, developing and implementing new clinical pharmacology approaches, contributing to program strategy and study design, working closely with research and development teams, representing nonclinical and clinical pharmacology during meetings with regulatory authorities, and reviewing literature and publications to stay informed on regulatory developments. They will also create or guide summary documents and contribute to diligence assessments.

Skills

Clinical Pharmacology
PK
PD
Immunogenicity
Data Synthesis
Team Leadership
Cross-functional Collaboration
Diligence Assessment

Amylyx Pharmaceuticals

Develops treatments for neurodegenerative diseases

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Key Metrics

Cambridge, MassachusettsHeadquarters
2013Year Founded
$166.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Remote Work Options

Risks

Relyvrio's Phase III failure raises concerns about ALS treatment efficacy.
Low stock offering price suggests potential financial instability.
New CCO may disrupt commercialization strategies if not aligned with goals.

Differentiation

Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.
AMX0035 is a promising drug for ALS and Alzheimer's treatment.
Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Upsides

Positive Phase II results for AMX0035 in ALS boost its potential.
Partnership with Gubra accelerates drug development for neurodegenerative diseases.
Regulatory support for rare diseases aids Amylyx's Wolfram syndrome efforts.

Land your dream remote job 3x faster with AI